Alzheimer's stunner: Chinese biotech wins OK for a new drug on positive data — and they have some high-profile supporters
Did an obscure Chinese biotech just crack the Alzheimer’s enigma that’s dumbfounded a host of major league drug developers?
China’s National Medical Products Administration revealed late Friday that it’s granted conditional approval for Shanghai Green Valley Pharma’s oligomannate capsules to improve cognitive functions in patients with mild-to-moderate Alzheimer’s, finding an overnight oasis in a therapeutic desert. The decision, which followed a fast-track review, was based on a purported Phase III win that the company has yet to dissect in detail.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.